Connect with us

The 2022 Best Countries Report Ranks Switzerland as No. 1 in the World

The 2022 Best Countries Report Ranks Switzerland as No. 1 in the World
PR Newswire
WASHINGTON, Sept. 27, 2022

Quality of life factors as most important for rankings.
WASHINGTON, Sept. 27, 2022 /PRNewswire/ — Switzerland returns to the top spot in …

Published

on

The 2022 Best Countries Report Ranks Switzerland as No. 1 in the World

PR Newswire

Quality of life factors as most important for rankings.

WASHINGTON, Sept. 27, 2022 /PRNewswire/ -- Switzerland returns to the top spot in the overall 2022 Best Countries, a ranking and analysis project by U.S. News & World Report; BAV Group, a unit of global marketing communications company WPP; and the Wharton School of the University of Pennsylvania. 

Now in its seventh year, Best Countries evaluates 85 countries across 73 attributes. Attributes were grouped into 10 subrankings, including entrepreneurship, agility and social purpose. Quality of life became the most heavily weighted subranking this year, as determined by the most recent gross domestic product per capita data. 

"The Best Countries rankings are designed to help policymakers and residents identify how perceptions affect their country's standing among other nations," said Kim Castro, editor and chief content officer at U.S. News. "Having quality of life as the top subranking demonstrates that elements such as a good job market, affordability, political stability and well-developed health and education systems are playing an increasingly important role in shaping a country's global image." 

For the fifth time, Switzerland claimed the No. 1 spot, with Germany coming in at No. 2, followed by Canada at No. 3. The United States moved up two positions to No. 4, followed by Sweden at No. 5.

Key themes from the 2022 Best Countries Report:

  • Switzerland returns to No. 1. The country, which held the top spot from 2017 to 2020, scored well on quality of life and social purpose attributes. It is also perceived as a country that cares about human rights, as well as gender and racial equity and the environment.
  • The Russia-Ukraine War influenced perceptions of those two countries and neighboring nations. Russia dropped to No. 36 in the Best Countries overall rankings, while Ukraine moved up to No. 62. Poland, Lithuania and Romania also moved up in the rankings.
  • The fear of rising inflation and economic decline is a top concern. Eighty-five percent of survey respondents believe inflation will worsen. Among survey participants, 58% agree with the statement, "I am willing to pay higher prices if it helps put more economic pressure on Russia."
  • COVID-19 continues to factor into perceptions of health care. Seventy-nine percent of respondents agree with the statement, "I approve of my country's efforts to protect its citizens from the COVID-19 pandemic," while only 65% agree with the statement, "I trust my government to take care of my health and safety."
  • There is a desire for global leadership – as well as female leadership. Eighty-nine percent agree with the statement, "We need leaders that think beyond their own borders or their own self-interests," while 69% agree that "countries led by women tend to be better managed," up 1.4 points from last year.

"This year we can truly see the growing significance of soft power over traditional forms of hard power when rating a country's standing in the world," said John Keaveney, advisor at BAV@WPP. "With the rise of importance in quality of life and social purpose in the Best Countries analysis and the declining prominence of military and economic might, we can see how much the general attitudes of the world are changing, and what nations need to consider."

The 2022 Best Countries rankings methodology is based on a proprietary survey of more than 17,000 global citizens from 36 countries, including business leaders, college-educated individuals who are middle-class or higher; and general citizens who are nationally representative of their country.

"In general, countries do not shift to any great degree from year to year," said David Reibstein, professor of marketing at the Wharton School. "But in 2021 and 2022, we witnessed more turmoil than in any of the previous seven years of this study, resulting in more change in how people viewed countries. Perhaps the greatest shakeup influencing the rankings this year is the conflict in Ukraine, the insecurity within Europe itself, the threat of possible nuclear confrontation and the total disruption of energy supplies."

The Best Countries rankings are part of U.S. News' government rankings initiative, which measures government performance at the international, state and local levels and includes the Best States and Healthiest Communities projects.

2022 Best Countries Rankings
See the full rankings here.

Overall

  1. Switzerland
  2. Germany
  3. Canada
  4. United States
  5. Sweden
  6. Japan
  7. Australia
  8. United Kingdom
  9. France
  10. Denmark

Most Powerful

  1. United States
  2. China 
  3. Russia

Most Agile   

  1. United States 
  2. Germany
  3. Canada

For Social Purpose

  1. Sweden
  2. Norway
  3. Denmark

For Women 

  1. Sweden
  2. Norway
  3. Finland

Most Forward-Looking

  1. Singapore
  2. Japan
  3. United States

For Racial Equality

  1. Netherlands
  2. Sweden
  3. Norway

For more information, visit Best Countries and use #BestCountries on Facebook and Twitter.

About U.S. News & World Report
U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C.

About BAV Group
BAV Group is a global consultancy with expertise in consumer insights and brand marketing strategy. Using BrandAsset® Valuator, a proprietary brand management tool and global database of consumer perceptions of brands, BAV informs strategic and creative solutions that drive business results. Over 29 years, BAV has captured data and consumer insights on more than 60,000 brands in 50+ countries around the world, evaluating 75 brand image and equity dimensions that matter. BAV Group is a unit of global marketing communications company WPP. Visit bavgroup.com to learn more.

About the Wharton School
Founded in 1881 as the world's first collegiate business school, the Wharton School of the University of Pennsylvania is shaping the future of business by incubating ideas, driving insights, and creating leaders who change the world. With a faculty of more than 235 renowned professors, Wharton has 5,000 undergraduate, MBA, executive MBA, and doctoral  students. Each year 13,000 professionals from around the world advance their careers through Wharton Executive Education's individual, company- customized, and online programs. More than 104,000 Wharton alumni form a powerful global network of leaders who transform business every day. For more information, visit www.wharton.upenn.edu.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-2022-best-countries-report-ranks-switzerland-as-no-1-in-the-world-301632385.html

SOURCE U.S. News & World Report, L.P.

Read More

Continue Reading

Uncategorized

nTIDE November 2022 Jobs Report: People with disabilities continue to outperform people without disabilities in labor market

East Hanover, NJ – December 2, 2022 – Job numbers rose again for people with disabilities, in contrast to people without disabilities, according to…

Published

on

East Hanover, NJ – December 2, 2022 – Job numbers rose again for people with disabilities, in contrast to people without disabilities, according to today’s National Trends in Disability Employment – Monthly Update (nTIDE), issued by Kessler Foundation and the University of New Hampshire’s Institute on Disability (UNH-IOD). People with disabilities continued to show strength in the labor market in November, as evidenced by the substantial rise in their employment-to-population ratio.

Credit: Kessler Foundation

East Hanover, NJ – December 2, 2022 – Job numbers rose again for people with disabilities, in contrast to people without disabilities, according to today’s National Trends in Disability Employment – Monthly Update (nTIDE), issued by Kessler Foundation and the University of New Hampshire’s Institute on Disability (UNH-IOD). People with disabilities continued to show strength in the labor market in November, as evidenced by the substantial rise in their employment-to-population ratio.

Month-to-Month nTIDE Numbers (comparing October 2022 to November 2022)

Based on data from the U.S. Bureau of Labor Statistics (BLS) Jobs Report released today, the employment-to-population ratio for people with disabilities (ages 16-64) increased from 35.5 percent in October to 36.5 percent in November (up 2.8 percent or 1 percentage point). For people without disabilities (ages 16-64), the employment-to-population ratio decreased from 74.6 percent in October to 74.4 percent in November (down 0.3 percent or 0.2 percentage point). The employment-to-population ratio, a key indicator, reflects the percentage of people who are working relative to the total population (the number of people working divided by the number of people in the total population multiplied by 100).

“Similar to last month, the employment-to-population ratio for people with disabilities increased and remains above historic highs. For those without disabilities, however, the ratio dropped,” said John O’Neill, PhD, director of the Center for Employment and Disability Research at Kessler Foundation. “This decline may be a sign of the Fed’s efforts to slow the labor market. This is interesting in light of this month’s strong gain for people with disabilities.”

Findings were similar for November’s labor force participation rate. For people with disabilities (ages 16-64), the labor force participation rate was increased slightly from 38.7 percent in October to 38.8 percent in November (up 0.3 percent or 0.1 percentage point). Conversely, the labor force participation rate decreased slightly for people without disabilities (ages 16-64), from 77.1 percent in October to 76.9 percent in November (down 0.3 percent or 0.2 percentage point). The labor force participation rate is the percentage of the population that is working, not working, and on temporary layoff, or not working and actively looking for work.

“While labor force participation for people with disabilities remains stable, increases in the employment to population ratio for people with disabilities suggest that more people with disabilities are succeeding in finding jobs,” remarked Debra Brucker, PhD, research associate professor at the UNH-IOD. “Keep in mind that gains in employment may in part reflect the need to boost income in the face of rising prices. Also, these data are not seasonally adjusted, so some of this increase may be due to seasonal employment.”

Why have people with disabilities been outperforming people without disabilities? Favorable changes in the workplace as employers adapted to COVID-19 restrictions may be a factor. Our new survey compares the workplaces of 2017 and 2022, revealing gains in recruiting, hiring, accommodating, and retaining employees with disabilities. Read more about the 2022 National Employment & Disability Survey: Effects of COVID-19 Pandemic Supervisor Perspectives.

Year-to-Year nTIDE Numbers (Comparing November 2021 to November 2022)

Reflecting the continued strength of the employment of people with disabilities over the course of the year, the employment-to-population ratio for working-age people with disabilities increased substantially from 34.6 percent in November 2021 to 36.5 percent in November 2022 (up 5.5 percent or 1.9 percentage points). However, the employment-to-population ratio increased slightly for working-age people without disabilities, from 73.8 percent in November 2021 to 74.4 percent in November 2022 (up 0.8 percent or 0.6 percentage points).

Similarly, for people with disabilities (16-64), the labor force participation rate increased substantially from 37.7 percent in November 2021 to 38.8 percent in November 2022 (up 2.9 percent or 1.1 percentage points). The labor force participation rate increased slightly for people without disabilities (ages 16-64), from 76.7 percent in November 2021 to 76.9 percent in November 2022 (up 0.3 percent or 0.2 percentage points).

In November, among workers ages 16-64, the 5,962,000 workers with disabilities represented 4 percent of the total 148,009,000 workers in the U.S.

Ask Questions about Disability and Employment

Each nTIDE release is followed by an nTIDE Lunch & Learn online webinar. This live broadcast, hosted via Zoom Webinar, offers attendees Q&A on the latest nTIDE findings, provides news and updates from the field, as well as invited panelists to discuss current disability-related findings and events. On December 2, 2022 at 12:00 pm Eastern, Chai Feldblum, JD, vice chair the of Ability One Commission, a federal agency devoted to the employment of people with significant disabilities, joins Drs. O’Neill and Brucker, and Denise Rozell, Policy Strategist at the Association of University Centers on Disabilities (AUCD). Join our Lunch & Learns live or visit the nTIDE archives at: ResearchonDisability.org/nTIDE.

NOTE: The statistics in the nTIDE are based on Bureau of Labor Statistics numbers but are not identical. They are customized by UNH to combine the statistics for men and women of working age (16 to 64). nTIDE is funded, in part, by grants from the National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR) (90RT5037) and Kessler Foundation.

About the Institute on Disability at the University of New Hampshire

The Institute on Disability (IOD) at the University of New Hampshire (UNH) was established in 1987 to provide a university-based focus for the improvement of knowledge, policies, and practices related to the lives of persons with disabilities and their families. For information on the NIDILRR-funded Research and Training Center on Disability Statistics, visit ResearchOnDisability.org.

About Kessler Foundation

Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research that seeks to improve cognition, mobility, and long-term outcomes – including employment – for people with neurological disabilities caused by diseases and injuries of the brain and spinal cord. Kessler Foundation leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities. For more information, visit KesslerFoundation.org.

Stay Connected with Kessler Foundation

Twitter | Facebook | YouTube | Instagram | iTunes & SoundCloud

To interview an expert, contact:

Deborah Hauss, DHauss@kesslerfoundation.org;

Carolann Murphy, CMurphy@KesslerFoundation.org.

 

 


Read More

Continue Reading

International

Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach

NEW YORK and LA JOLLA, CA—While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being…

Published

on

NEW YORK and LA JOLLA, CA—While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being pursued by researchers at Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) shows new promise, according to data from a first-in-human clinical trial.

Credit: CHRISTOPHER COTTRELL, CREATED WITH BIORENDER.COM

NEW YORK and LA JOLLA, CA—While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being pursued by researchers at Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) shows new promise, according to data from a first-in-human clinical trial.

In a paper published in Science on December 2, 2022, the scientists reveal critical new insights into their novel vaccine strategy, which involves a stepwise approach to producing antibodies capable of targeting a wide range of HIV variants. 

“The data we are publishing in Science demonstrates for the first time that one can design a vaccine that elicits made-to-order antibodies in humans. We specified in advance certain molecular properties of the antibodies that we wanted to elicit, and the results of this trial show that our vaccine antigen consistently induced precisely those types of antibodies,” says co-senior author William Schief, PhD, a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI’s Neutralizing Antibody Center, whose laboratory developed the vaccine antigen. “We believe this vaccine design strategy will be essential to make an HIV vaccine and may help the field create vaccines for other difficult pathogens.”

The Phase 1 trial, known as IAVI G001, tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing. The trial results show that the vaccine had a favorable safety profile and induced the targeted response in 97% of people who were vaccinated. Importantly, the Science study also provides a detailed immunological analysis of the vaccine responses.

“HIV represents an area of dire unmet need across the world, which is what makes the findings from our Phase 1 clinical trial so encouraging,” says Mark Feinberg, MD, PhD, president and CEO of IAVI. “Through the close-knit collaboration of many different scientists, disciplines and institutions, we are that much closer to designing an effective vaccine that could help end the HIV pandemic.”  

Priming the Immune System

Broadly neutralizing antibodies (bnAbs) are a rare type of antibody that can fight and protect against many different variants of a virus—including HIV. This is why scientists have tried to develop an HIV vaccine that induces bnAbs, but thus far without success.   

The researchers in the study are using a strategy known as ‘germline targeting’ to eventually produce bnAbs that can protect against HIV. The first step of germline targeting involves stimulating the rare immune cells—known as bnAb-precursor B cells—that can eventually evolve into the cells that produce the bnAbs needed to block the virus. To accomplish this first step, the researchers designed a customized molecule—known as an immunogen—that would “prime” the immune system and elicit responses from these rare bnAb-precursor cells.

The overarching goal of the IAVI G001 trial was to determine if the vaccine had an acceptable safety profile and could induce responses from these bnAb-precursor B cells.

“Through extensive safety and tolerability monitoring during the trial, we showed the vaccine had a favorable safety profile, while still inducing the necessary target cells,” says study author Dagna Laufer, MD, vice president and head of clinical development at IAVI. “This represents a large step forward in developing an HIV vaccine that is both safe and effective.”

To determine if the targeted bnAb-precursor B cells were induced, the researchers carried out a sophisticated analytical process.

“The workflow of multidimensional immunological analyses has taken clinical trial evaluation to the next level,” says co-senior author Adrian B. McDermott, PhD, former chief of the Vaccine Immunology Program at the NIAID VRC. “In evaluating these important immunological factors, we helped show why the vaccine antigen was able to induce the targeted response in 97% of vaccine recipients.” 

IAVI G001 was sponsored by IAVI and took place at two sites: George Washington University (GWU) in Washington, D.C., and Fred Hutch in Seattle, enrolling 48 healthy adult volunteers. Participants received either a placebo or two doses of the vaccine antigen, eOD-GT8 60mer, along with an adjuvant developed by the pharmaceutical company GSK. Julie McElrath, MD, PhD, co-senior author, senior vice president and director of Fred Hutch’s Vaccine and Infectious Disease Division, and David Diemert, MD, professor of medicine at GWU School of Medicine and Health Sciences, were lead investigators at the trial sites.

A Deeper Immunological Dive

The study also carefully examined the properties of the antibodies and B cells induced by the vaccine antigen, in what Schief likens to “looking under the car hood” to understand how the immune system operated in response to the vaccine. One analysis showed that the vaccine antigen first stimulated an average of 30 to 65 different bnAb precursors per person vaccinated, and then caused those cells to multiply. This helped explain why the vaccine induced the desired response in almost all participants.

Other analyses delved into the specific mutations the bnAb-precursor B cells acquired over time and how tightly they bound to the vaccine antigen. These investigations showed that that after each dose of the vaccine, the bnAb-precursor B cells gained affinity and continued along favorable maturation pathways.

One concern for this type of vaccine approach is the notion of “competitors”—in other words, the B cells induced by the vaccine antigen that are not bnAb precursors. The researchers extensively studied the “competitor” responses, and the results were very encouraging. Although the majority of the B cells triggered by vaccination were, in fact, “competitors”, these undesired B cells could not match the binding strength of the desired bnAb precursors and did not seem to impede maturation of the bnAb-precursor responses.

“These findings were very encouraging, as they indicated that immunogen design principles we used could be applied to many different epitopes, whether for HIV or even other pathogens,” adds Schief.

With these promising data in hand spanning both safety and immune responses, the researchers will continue to iterate and design boosting immunogens that could eventually induce the desired bnAbs and provide protection against the virus. These findings also come shortly after two additional studies in Immunity published in September 2022, which helped validate the germline-targeting approach for vaccinating against HIV.

“Working together with IAVI, Scripps Research, the VRC, GWU, additional investigators at Fred Hutch and many others, this trial and additional analyses will help inform design of the remaining stages of a candidate HIV vaccine regimen—while also enabling others in the field to develop vaccine strategies for additional viruses,” says McElrath of Fred Hutch.

IAVI, Scripps Research, NIAID, the Bill & Melinda Gates Foundation and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID) are partnering with the biotechnology company Moderna to develop and test mRNA delivery of these HIV vaccine antigens. Two Phase I clinical trials are underway that build on IAVI G001, one (IAVI G002) at four sites in the U.S. and another (IAVI G003) at the Center for Family Health Research in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa. Both are testing mRNA delivery of the eOD-GT8 60mer that was evaluated as recombinant protein in IAVI G001, and the U.S. trial includes a boost antigen designed by the Schief lab and delivered with Moderna mRNA technology. A third trial (HVTN302), at ten sites in the U.S., is testing mRNA delivery of three different stabilized HIV trimers designed in the Schief laboratory that are candidates for late-stage boosters in multi-stage vaccines aiming to induce bnAbs. Using mRNA technology could significantly accelerate the pace of HIV vaccine development as it allows for faster production of clinical trial material.

This work was supported by the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery; the IAVI Neutralizing Antibody Center; NIAID; Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery and Scripps Consortium for HIV/AIDS Vaccine Development; and the Ragon Institute of MGH, MIT, and Harvard. Other collaborating organizations include Duke Human Vaccine Institute, Karolinska Institutet, and La Jolla Institute. 

Research at the IAVI Neutralizing Antibody Center that contributed to the development of the vaccine antigen eOD-GT8 60mer was also made possible by the government of the Netherlands through the Minister of Foreign Trade & Development Cooperation and through the generous support of the American people through PEPFAR through USAID. The contents are the responsibility of IAVI and Scripps Research and do not necessarily reflect the views of PEPFAR, USAID, or the United States government.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

About Scripps Research

Scripps Research is an independent, nonprofit biomedical institute ranked the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at www.scripps.edu.


Read More

Continue Reading

Uncategorized

US nonfarm payrolls surpass expectations to rise by 263,000; Wages up by the sharpest in 13 months

In a highly unexpected development, U.S. nonfarm payrolls outperformed market expectations and rose by 263,000 in the month of November. This was against…

Published

on

In a highly unexpected development, U.S. nonfarm payrolls outperformed market expectations and rose by 263,000 in the month of November.

This was against market estimates of a slowdown to 200,000.

The unemployment rate was also unchanged and stayed near fifty-year lows at 3.7%.

The recent ADP report missed its mark once more, having forecast a steep dip in jobs, almost halving October’s figures.

October data was revised upwards to 284,000, higher than the preliminary data for November, as compared to the initial report of 261,000 (which I covered here for Invezz).

September data which came in at a strong 315,000 has been revised sharply downwards to 269,000.

Source: TradingEconomics.com

Gains were highest in leisure and hospitality (88,000), health care (45,000), and government (42,000) which were concentrated at the local levels.

Payroll reductions were seen in retail (-32,000) and warehousing and storage (-13,000).

The November uptick is robust compared to average pre-pandemic levels, suggesting that the Fed’s tightening has not yet managed to sufficiently curb labour market strength.

Having said that, monthly additions have largely continued to cool through the second half of the year.

Earnings

Average hourly earnings, month-over-month rose sharply by 0.6% to $32.82, as against expectations of a rise of 0.3%.  This amounted to the sharpest rise in 13 months.

Similarly, on an annual basis, hourly earnings went up 5.1% as against forecasts of 4.6% and improved over October’s 4.7%.

Due to higher wages, the Fed will likely find inflationary pressures staying firmer than earlier anticipated, and price stability elusive.

Outlook

Although there have been reports of mass layoffs in technology companies and the banking sector, the labour market headline for the last month is still relatively firm.

This will be highly frustrating for policymakers who have already executed four 75bps rate hikes this year.

As per the CME FedWatch Tool, there is a 74.7% likelihood of a downshift in rate hikes to 50 bps later this month, but this report may delay discussions of a pivot.

Do check out our other economic analysis that can be found here.

The post US nonfarm payrolls surpass expectations to rise by 263,000; Wages up by the sharpest in 13 months appeared first on Invezz.

Read More

Continue Reading

Trending